KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.

D P Carbone, T-E Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, E Richardet, E Felip, Y Cheng, O Juan-Vidal, A Alexandru, H Mizutani, N Reinmuth, S Lu, M Reck, T John, A Scherpereel, P De Marchi, T Aoyama, P Sathyanarayana, D J Grootendorst, N Hu, V Ip, Y-H Hung, L G Paz-Ares

ESMO Open 10(6) 105123

PMID40446626
PMCIDPMC12166824
DOI10.1016/j.esmoop.2025.105123
发表日期2025-05-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:森林图/亚组分析图;Figure 5:非 KM 图。
摘要

摘要

BACKGROUND: The phase III CheckMate 9LA study demonstrated durable overall survival (OS) benefit with nivolumab plus ipilimumab with chemotherapy versus chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Here, we report final, 6-year efficacy and safety outcomes. PATIENTS AND METHODS: Treatment-naive adults with stage IV/recurrent NSCLC and no sensitizing EGFR/ALK alterations were randomized to nivolumab plus ipilimumab with chemotherapy (n = 361) or chemotherapy (n = 358). Assessments included OS, progression-free survival, objective response rate, and duration of response (DOR) in all randomized patients and subgroups, and OS by select somatic mutation status (KRAS, STK11, KEAP1, and TP53). RESULTS: With 68.6 months' minimum follow-up, nivolumab plus ipilimumab with chemotherapy demonstrated continued OS benefit versus chemotherapy (hazard ratio 0.74, 95% confidence interval 0.63-0.87, 6-year OS rates 16% versus 10%), regardless of tumor programmed death ligand 1 (PD-L1) expression (PD-L1 <1%, 20% versus 7%; PD-L1 ≥1%, 15% versus 10%) and histology (squamous, 14% versus 5%; non-squamous, 17% versus 12%). The 6-year DOR rate was 19% with nivolumab plus ipilimumab with chemotherapy; all patients in the chemotherapy arm were censored or stopped responding before this timepoint. Trends toward improved OS were observed with nivolumab plus ipilimumab with chemotherapy over chemotherapy regardless of KRAS, STK11, KEAP1, or TP53 mutation status. No new safety signals were observed. CONCLUSIONS: These final analyses demonstrate the durable, long-term OS and response benefit with first-line nivolumab plus ipilimumab with chemotherapy over chemotherapy in patients with metastatic NSCLC, regardless of tumor PD-L1 expression, histology, or select somatic mutation status, further supporting this regimen as a standard-of-care treatment option.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1OS in (A) all randomized patients, and in patients with (B) tumor PD-L1 <1%, (C) tumor PD-L1 ≥1%, (D) squamous tumor histology, and (E) non-squamous tumor histology. Minimum follow-up for OS was 68.6 months. Chemo, chemotherapy; CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; PD-L1, programmed death ligand 1.
非 KM Figure
Figure 2DOR in (A) all randomized patients, and in patients with (B) tumor PD-L1 <1%, (C) tumor PD-L1 ≥1%, (D) squamous tumor histology, and (E) non-squamous tumor histology. DOR was per blinded independent central review according to Response Evaluation Criteria in Solid Tumors v1.1. Chemo, chemotherapy; CI, confidence interval; DOR, duration of response; IPI, ipilimumab; NA, not available; NIVO, nivolumab; ORR, objective response rate; PD-L1, programmed death ligand 1. a Rate is reported as NA because all patients with continuing response in the chemo arm were censored before 72 months.
非 KM Figure
Figure 3OS in patients who discontinued due to TRAEs. Adverse events were reported between the first dose and 30 days after the last dose of study treatment and led to discontinuation of all components of study treatment. Minimum follow-up for OS was 68.6 months. Chemo, chemotherapy; CI, confidence interval; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; TRAE, treatment-related adverse event.
非 KM Figure
Figure 4OS by select mutation status: (A) KRAS mutant (non-squamous only), (B) KRAS wild-type (non-squamous only), (C) STK11 mutant (non-squamous only), (D) STK11 wild-type (non-squamous only), (E) TP53 mutant, and (F) TP53 wild-type. Minimum follow-up for OS was 68.6 months. Chemo, chemotherapy; CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival.
非 KM Figure
Figure 5Genomic mutation status in long-term (≥6-year) survivors. Data within the bars represent the number of patients with wild-type or mutant tumors. Chemo, chemotherapy; IPI, ipilimumab; NIVO, nivolumab; NSCLC, non-small-cell lung cancer. a Non-squamous NSCLC only.
非 KM Figure